It's far more effective than we initially expected
Candida auris cases in Spain total 1,807 since 2016—nearly half of Europe's cases—prompting a September 2025 European alert as the fungus becomes endemic in hospitals across five continents. Molecular's green chemistry solution eliminates toxic substances while delivering superior microbicidal power, representing a breakthrough after current disinfectants failed to contain the fungus's 500% increase in five years.
- Spain: 1,807 Candida auris cases since 2016—nearly half of Europe's total
- Molecular's molecules are 60+ times more potent than current antifungal treatments
- Regulatory approval timeline: 18-24 months pending validation
- Candida auris infections increased 500% in five years; can cause fatal disease in 90 days
- Molecular secured €186,000 funding from BeAble Capital in September 2025
Molecular, a Spanish spinoff from Universitat Jaume I, has developed molecules 60 times more effective than current antifungal treatments against Candida auris, a deadly hospital fungus spreading across Europe with Spain leading in cases.
A Spanish research team has engineered molecules that kill the fungus Candida auris with a force more than sixty times greater than anything hospitals currently use to fight it. The breakthrough comes as this pathogen spreads across Europe with alarming speed, and Spain sits at the center of the crisis.
On September 11, 2025, the European Centre for Disease Prevention and Control issued a formal alert about Candida auris. The numbers are stark: Spain has recorded 1,807 cases since the fungus was first detected in 2016—nearly half of all European cases. What began as isolated outbreaks in Madrid, Barcelona, and Mallorca has metastasized into what health authorities now call an endemic situation, meaning the fungus is no longer confined to occasional clusters but has become a recurring presence across hospitals on five continents. The World Health Organization ranks it among the nineteen most dangerous infectious fungi threatening public health.
The fungus moves fast and kills efficiently. It can establish a fatal infection within ninety days of exposure. Over the past five years, cases have surged by more than five hundred percent. Climate change appears to be accelerating its spread. Standard disinfectants and antifungal treatments have failed to contain it. Hospitals have thrown their current arsenal at the problem and watched it advance anyway.
Molecular, a spinoff company born from Universitat Jaume I in Castellón, may offer a way out. The team—cofounded by Eduardo García-Verdugo and Carlos Estévez Company—spent years developing what they call green chemistry: sterilizing agents that work without toxic or hazardous substances. Laboratory validation has already confirmed that their molecules deliver superior killing power. García-Verdugo says the results surprised even the founders. "We thought it would be better," he explains, "but the testing showed it's far more effective than we initially expected."
The company was launched in 2023. This month, it closed a funding round of 186,000 euros from BeAble Capital, an investment fund that has backed more than forty Spanish companies since 2018, focusing on disruptive and sustainable technologies in sectors critical to the economy. The capital will fund the regulatory validation work still required before Molecular's products can reach the market. That process typically takes between eighteen months and two years, though Estévez notes that the public health emergency surrounding Candida auris might compress the timeline—much as COVID-19 accelerated vaccine approvals.
What makes this technology distinct is not just its potency but its safety profile. Traditional sterilizing agents rely on substances that pose risks to people and the environment. Molecular's approach eliminates that trade-off. If approved, it could establish a new standard not only in hospitals and clinics but across industries that depend on sterilization. Estévez is hopeful that once the regulatory pathway clears, the company's green chemistry could reshape how the world thinks about disinfection itself.
For now, the fungus continues its advance. The recent European alert makes clear that existing solutions have not slowed it. Molecular's molecules represent the most concrete hope on the horizon—a Spanish answer to a continental crisis, waiting for the bureaucratic machinery to turn.
Citações Notáveis
The fungus has entered a phase experts call endemic—no longer isolated cases, but recurring across many hospitals on five continents— Carlos Estévez, Molecular cofounder
Our solution represents a qualitative leap beyond all sterilizing products currently on the market— Eduardo García-Verdugo, Molecular cofounder
A Conversa do Hearth Outra perspectiva sobre a história
Why is Spain being hit so much harder than other European countries?
The source doesn't explain the epidemiological reason—just that Spain leads in cases. It could be detection patterns, hospital density, climate factors, or reporting differences. The alert flags it as a fact, not a mystery the article solves.
How confident are the founders that this will actually work in real hospitals, not just in the lab?
They've done lab validation and it exceeded their own expectations. But they're honest about what comes next: regulatory testing. They're not claiming victory yet, just that the early signs are genuinely surprising.
What happens if the fungus mutates and becomes resistant to this new treatment too?
The source doesn't address that risk. It's a fair question—resistance is always a threat with antimicrobials. But the founders seem focused on the immediate crisis: current tools aren't working, and this one is orders of magnitude more potent.
Why does it matter that it's green chemistry, beyond the marketing angle?
Because hospitals and industries have always accepted toxic trade-offs as the cost of sterilization. If you can kill the fungus without those poisons, you've solved two problems at once: the infection and the collateral damage. That's genuinely different.
Could this accelerate approval the way COVID did?
The founders think the urgency might help. But they're careful—they say it could happen, not that it will. The regulatory bar for something that touches hospital environments is very high. Desperation helps, but it doesn't erase the need for proof.